Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats

Stroke

Volumn 29, Issue 1, 1998, Pages 152-158

  Markgraf, Carrie G ^a   Velayo, Nelson L ^a   Johnson, Michael P ^a   McCarty, Deborah R ^a   Medhi, Shujaath ^a   Koehl, Jack R ^a   Chmielewski, Paula A ^a,b   Linnik, Matthew D ^a,c  

^a SANOFI   (France)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c CNS Molecular Biology   (United States)

Author keywords

Calpain; Calpain inhibitor; Cerebral ischemia; Focal neuroprotection

Indexed keywords

CALPAIN; CALPASTATIN; CATHEPSIN B; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SPECIFICITY; IMAGE ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; RAT;

EID: 0031984802     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.1.152     Document Type: Article

References (34)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Barsan WG, Brott TG, Broderick JP, Haley EC, Levy DE, Marler JR. Time of hospital presentation in patients with acute stroke. Arch Intern Med. 1993;153:2558-2561.
3. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986;19:105-111.
4. Croall DE, Demartino GN. Calcium-activated neutral proteinase (calpain) system: structure, function and regulation. Physiol Rev. 1991;71:813-847.
5. Bartus RT, Dean RL, Cavanaugh K, Eveleth D, Carriero DL, Lynch G. Time-related neuronal changes following middle cerebral artery occlusion: implications for therapeutic intervention and the role of calpain. J Cereb Blood Flow Metab. 1995;15:969-979.
6. Yao H, Ginsberg MD, Eveleth DD, LaManna JC, Watson BD, Alonso OF, Loor JY, Foreman JH, Busto R. Local cerebral glucose utilization and cytoskeletal proteolysis as indices of evolving focal ischemic injury in core and penumbra. J Cereb Blood Flow Metab. 1995;15:398-408.
7. Yokota M, Saido TC, Tani E, Kawashima S, Suzuki K. Three distinct phases of fodrin proteolysis induced in postischemic hippocampus. Involvement of calpain and unidentified protease. Stroke. 1995;26: 1901-1907.
8. Bartus RT, Hayward NJ, Elliott PJ, Sawyer SD, Baker KL, Dean RL, Akiyama A, Straub JA, Harbeson SL, Li Z, Powers J. Calpain inhibitor AK295 protects neurons from focal brain ischemia. Stroke. 1994;25: 2265-2270.
9. Bartus RT, Baker KL, Heiser AD, Sawyer SD, Dean RL, Elliott PJ, Straub JA. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection agonist focal ischemic brain damage. J Cereb Blood Flow Metab. 1994;14:537-544.
10. Hong S-C, Goto Y, Lanzino G, Soleau S, Kassell NF, Lee KS. Neuro-protection with a calpain inhibitor in a model of focal cerebral ischemia. Stroke. 1994;25:663-669.
11. Lee KS, Frank S, Vanderklish P, Arai A, Lynch G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc Natl Acad Sci U S A. 1991;88:7233-7237.
12. Zea Longa E, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20: 84-91.
13. Garcia JH, Liu KF, Ho KL. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudaputamen and the cortex. Stroke. 1995;26:636-643.
14. Arlinghaus L, Mehdi S, Lee KS. Improved posthypoxic recovery with a membrane-permeable calpain inhibitor. Eur J Pharmacol. 1991;209: 123-125.
15. Hiramatsu K, Kassell NF, Lee KS. Improved posthypoxic recovery of synaptic transmission in gerbil neocortical slices treated with a calpain inhibitor. Stroke. 1993;24:1725-1728.
16. Rami A, Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res. 1993;609:67-70.
17. Caner H, Collins JL, Harris SM, Kassell NF, Lee KS. Attenuation of AMPA-induced neurotoxicity by a calpain inhibitor. Brain Res. 1993;607: 354-356.
18. Brorson JR, Marcuccilli CJ, Miller RJ. Delayed antagonism of calpain reduces excitotoxicity in cultured neurons. Stroke. 1995 26;1259-1266.
19. Rami A, Ferger D, Krieglstein J. Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity. Neurosci Res. 1997;27: 93-97.
20. Squier MKT, Miller ACK, Malkinson AM, Cohen JJ. Calpain activation in apoptosis. J Cell Physiol. 1994;159:229-237.
21. Sarin A, Clerici M, Blatt SP, Hendrix CW, Shearer GM, Henkart PA. Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. J Immunol. 1994;153:862-872.
22. Martin SJ, O'Brien GA, Nishioka WK, McGahon GA, Mahboubi A, Saido TC, Green DR. Proteolysis of fodrin (non-erythroid spectrin) during apoptosis. J Biol Chem. 1995;270:6425-6428.
23. Linnik MD, Markgraf CG, Mason PJ, Velayo N, Racke MM. Calpain inhibition attenuates apoptosis in vitro and decreases infarct size in vivo. In: Krieglstein, J, ed. Pharmacology of Cerebral Ischemia 1996. Stuttgart, Germany: Medpharm Scientific Publishers; 1996:33-40.
24. Hiwasa T. Induction of apoptosis by a calpain stimulator, ONO-3403 Apoptosis 1996;1:75-80.
25. Linnik MD. Role of apoptosis in acute neurodegenerative disorders. Restor Neurol Neurosci. 1996;9:219-225.
26. Mehdi S. Cell-penetrating inhibitors of calpain. Trends Biol Sci. 1991;16: 150-153.
27. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, Shimizu-Sasamata M, Yuan J, Moskowitz MA. Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excicotoxic neuronal damage. Proc Natl Acad Sci U S A. 1997;94:2007-2012.
28. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res. 1982;239:57-69.
29. Du C, Hu R, Csemansky CA, Hsu CY, Choi DW. Very delayed infarction after mild focal cerebral ischemia: a role for apoptosis? J Cereb Blood Flow Metab. 1996;16:195-201.
30. Schmidt-Kastner R, Fliss H, Hakim AM. Subtle neuronal death in striatum after short forebrain ischemia in rats detected by in situ end-labeling for DNA damage. Stroke. 1997;28:163-170.
31. Bederson JA, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2,3,4-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 1986;17:1304-1308.
32. Park CK, Mendelow AD, Graham DI, McCulloch J, Teasdale GM. Correlation of triphenyltetrazolium chloride perfusion staining with conventional neurohistology in the detection of early brain ischemia. Neuropath Appl Neurobiol. 1988;14:289-298.
33. Goldlust EJ, Paczynski RP, He YY, Hsu CY, Goldberg MP. Automated measurement of infarct size with scanned images of triphenyltetrazolium chloride-stained rat brains. Stroke. 1996;27:1657-1662.
34. Wang KKW, Yuen P-W. Calpain inhibition: an overview of its therapeutic potential Trends Pharmacol Sci. 1994;15:412-419.